BioSpace News Archive

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Corcept Therapeutics Incorporated of the May 13, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Healthcare Services Group, Inc. of the May 21, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new data of the QIAstat-Dx Meningitis / Encephalitis panel. The panel is in late stage development and being prepared for CE-IVD commercialization in the second half of 2019 for use on the QIAstat-Dx multiplex syndromic testing system.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and Class A warrants to purchase its common stock. All of the securities in the offering will be sold by X4.

Global heart health technology leader secures FDA clearance on groundbreaking blood pressure monitor with EKG in a single device for home use

Rady Children’s Hospital-San Diego announced plans to partner with New Jersey’s Children’s Specialized Hospital, part of RWJBarnabas Health and a leading pediatric provider for children facing health care challenges including chronic pain and illness.

Alacura Medical Transportation Management, a transportation benefit management provider for healthcare insurance plans, is pleased to announce the appointment of Ken Van Cara as Chief Executive Officer.

Clinical quality was higher and total cost of care was lower for patient populations cared for by providers who share financial risk.

PetaGene, provider of state of the art compression technology for genomic data, today announced the addition of PetaSuite Protect to its award winning range of genomic data products.

Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat serious disorders of the nervous system, today announced the positive results of AUT00206 in a Phase Ib “ketamine challenge” study in healthy volunteers.